Snapshot from Jul 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Artelo Biosciences ART27.13...
Business clinical trial results

Artelo Biosciences ART27.13 Neuropathic Pain Results

Analysis based on 7 articles · First reported Jul 13, 2026 · Last updated Jul 13, 2026

Sentiment
10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive nonclinical data may support broader use of ART27.13 in cancer supportive care, potentially expanding its market opportunity. However, the stock declined, possibly due to the early-stage nature of the results or broader market factors.

Pharmaceuticals Biotechnology
Event Summary

Artelo Biosciences announced positive nonclinical results for ART27.13 in paclitaxel-induced peripheral neuropathy, a common chemotherapy side effect. The study showed reduced pain behaviors in animal models. ART27.13 is also in Phase 2 for cancer-related anorexia cachexia syndrome (CACS), with interim data showing weight gain and improved activity. The company presented findings at the ICRS 2026 symposium. ARTL stock fell about 4% on the day.

Key Actions
70 Artelo Biosciences announced results
50 Artelo Biosciences presented data International Cannabinoid Research Society
Entities Involved
stock
Artelo Biosciences
Artelo announced positive nonclinical results for ART27.13, supporting its pipeline in cancer supportive care. The stock declined slightly, reflecting mixed market reaction.
Importance 100.0 Sentiment 10.0
per
George Warren
Lead scientist at Artelo who presented the pain study results at ICRS.
Importance 20.0 Sentiment 0.0
per
Saoirse E. O Sullivan
VP of Translational Science at Artelo, presented interim CAReS results at ICRS.
Importance 20.0 Sentiment 0.0
stock
AstraZeneca
AstraZeneca originally developed ART27.13 but is not directly involved in this event.
Importance 10.0 Sentiment 0.0
ngo
International Cannabinoid Research Society
Hosted the symposium where Artelo presented its findings.
Importance 10.0 Sentiment 0.0
exch
Nasdaq
ARTL is listed on Nasdaq; stock price declined on announcement day.
Importance 5.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
No FDA-approved treatments exist for CACS, highlighting unmet need.
Importance 5.0 Sentiment 0.0
Relationships
AstraZeneca related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.